141 related articles for article (PubMed ID: 37386842)
21. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Ismail NF; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
[TBL] [Abstract][Full Text] [Related]
22. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
[TBL] [Abstract][Full Text] [Related]
23. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex.
Hatano T; Ohno Y; Imai Y; Moritake J; Endo K; Tamari M; Egawa S
Orphanet J Rare Dis; 2020 Jun; 15(1):133. PubMed ID: 32487130
[TBL] [Abstract][Full Text] [Related]
24. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
[TBL] [Abstract][Full Text] [Related]
25. Targeted topical and combination laser surgery for the treatment of angiofibromas.
Bae-Harboe YS; Geronemus RG
Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
[TBL] [Abstract][Full Text] [Related]
26. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
27. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial.
Aitken P; Stanescu I; Boddington L; Mahon C; Fogarasi A; Liao YH; Ivars M; Moreno-Artero E; Trauner D; DeRoos ST; Jancic J; Nikolic M; Balážová P; Price HN; Hadzsiev K; Riney K; Stapleton S; Tollefson MM; Bauer D; Pinková B; Atkinson H
Br J Dermatol; 2023 Oct; 189(5):520-530. PubMed ID: 37463422
[TBL] [Abstract][Full Text] [Related]
28. Topical rapamycin combined with calcitriol in treating angiofibromas in tuberous sclerosis complex.
Lee CH
Br J Dermatol; 2020 Oct; 183(4):604-606. PubMed ID: 32338383
[No Abstract] [Full Text] [Related]
29. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
30. Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.
Norrenberg S; Masconi M; Karamanou M; Meylan P; Golaz R; Christen-Zaech S
Br J Dermatol; 2018 Jul; 179(1):208-209. PubMed ID: 29380350
[No Abstract] [Full Text] [Related]
31. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Farges D; Sigg N; Ville D; Martin L
Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
[TBL] [Abstract][Full Text] [Related]
33. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
Boggarapu S; Roberds SL; Nakagawa J; Beresford E
Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
[TBL] [Abstract][Full Text] [Related]
34. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
35. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
[TBL] [Abstract][Full Text] [Related]
36. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
Kaufman McNamara E; Curtis AR; Fleischer AB
J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
[TBL] [Abstract][Full Text] [Related]
38. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
[TBL] [Abstract][Full Text] [Related]
39. Ambient-stable topical rapamycin cream is effective in treating angiofibromas in tuberous sclerosis complex.
Hong CH; Lee CH
Br J Dermatol; 2023 Oct; 189(5):507-508. PubMed ID: 37672663
[No Abstract] [Full Text] [Related]
40. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
Leducq S; Giraudeau B; Tavernier E; Maruani A
J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
